378 related articles for article (PubMed ID: 30843188)
21. Harmful effect of ERβ on BCRP-mediated drug resistance and cell proliferation in ERα/PR-negative breast cancer.
Li W; Jia M; Qin X; Hu J; Zhang X; Zhou G
FEBS J; 2013 Dec; 280(23):6128-40. PubMed ID: 24103091
[TBL] [Abstract][Full Text] [Related]
22. Crosstalk between progesterone receptor membrane component 1 and estrogen receptor α promotes breast cancer cell proliferation.
Pedroza DA; Subramani R; Tiula K; Do A; Rashiraj N; Galvez A; Chatterjee A; Bencomo A; Rivera S; Lakshmanaswamy R
Lab Invest; 2021 Jun; 101(6):733-744. PubMed ID: 33903732
[TBL] [Abstract][Full Text] [Related]
23. A set of accessible enhancers enables the initial response of breast cancer cells to physiological progestin concentrations.
Zaurin R; Ferrari R; Nacht AS; Carbonell J; Le Dily F; Font-Mateu J; de Llobet Cucalon LI; Vidal E; Lioutas A; Beato M; Vicent GP
Nucleic Acids Res; 2021 Dec; 49(22):12716-12731. PubMed ID: 34850111
[TBL] [Abstract][Full Text] [Related]
24. Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB1 or SMRT recruitment to the CCND1 and MYC promoters.
Wargon V; Riggio M; Giulianelli S; Sequeira GR; Rojas P; May M; Polo ML; Gorostiaga MA; Jacobsen B; Molinolo A; Novaro V; Lanari C
Int J Cancer; 2015 Jun; 136(11):2680-92. PubMed ID: 25363551
[TBL] [Abstract][Full Text] [Related]
25. Inverse Relationship between Progesterone Receptor and Myc in Endometrial Cancer.
Kavlashvili T; Jia Y; Dai D; Meng X; Thiel KW; Leslie KK; Yang S
PLoS One; 2016; 11(2):e0148912. PubMed ID: 26859414
[TBL] [Abstract][Full Text] [Related]
26. Protein kinases mediate ligand-independent derepression of sumoylated progesterone receptors in breast cancer cells.
Daniel AR; Lange CA
Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14287-92. PubMed ID: 19706513
[TBL] [Abstract][Full Text] [Related]
27. Effects of estriol on growth, gene expression and estrogen response element activation in human breast cancer cell lines.
Diller M; Schüler S; Buchholz S; Lattrich C; Treeck O; Ortmann O
Maturitas; 2014 Apr; 77(4):336-43. PubMed ID: 24529907
[TBL] [Abstract][Full Text] [Related]
28. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells.
Albanito L; Madeo A; Lappano R; Vivacqua A; Rago V; Carpino A; Oprea TI; Prossnitz ER; Musti AM; Andò S; Maggiolini M
Cancer Res; 2007 Feb; 67(4):1859-66. PubMed ID: 17308128
[TBL] [Abstract][Full Text] [Related]
29. Cyclin dependent kinase-9 mediated transcriptional de-regulation of cMYC as a critical determinant of endocrine-therapy resistance in breast cancers.
Sengupta S; Biarnes MC; Jordan VC
Breast Cancer Res Treat; 2014 Jan; 143(1):113-24. PubMed ID: 24309997
[TBL] [Abstract][Full Text] [Related]
30. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
31. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
32. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
[TBL] [Abstract][Full Text] [Related]
33. AIB1:ERα transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells.
O'Hara J; Vareslija D; McBryan J; Bane F; Tibbitts P; Byrne C; Conroy RM; Hao Y; Gaora PÓ; Hill AD; McIlroy M; Young LS
Clin Cancer Res; 2012 Jun; 18(12):3305-15. PubMed ID: 22550166
[TBL] [Abstract][Full Text] [Related]
34. Cooperative activation of cyclin D1 and progesterone receptor gene expression by the SRC-3 coactivator and SMRT corepressor.
Karmakar S; Gao T; Pace MC; Oesterreich S; Smith CL
Mol Endocrinol; 2010 Jun; 24(6):1187-202. PubMed ID: 20392877
[TBL] [Abstract][Full Text] [Related]
35. miR-190 enhances endocrine therapy sensitivity by regulating SOX9 expression in breast cancer.
Yu Y; Yin W; Yu ZH; Zhou YJ; Chi JR; Ge J; Cao XC
J Exp Clin Cancer Res; 2019 Jan; 38(1):22. PubMed ID: 30658681
[TBL] [Abstract][Full Text] [Related]
36. Estrogen induces c-myc gene expression via an upstream enhancer activated by the estrogen receptor and the AP-1 transcription factor.
Wang C; Mayer JA; Mazumdar A; Fertuck K; Kim H; Brown M; Brown PH
Mol Endocrinol; 2011 Sep; 25(9):1527-38. PubMed ID: 21835891
[TBL] [Abstract][Full Text] [Related]
37. RNA sequencing of MCF-7 breast cancer cells identifies novel estrogen-responsive genes with functional estrogen receptor-binding sites in the vicinity of their transcription start sites.
Yamaga R; Ikeda K; Horie-Inoue K; Ouchi Y; Suzuki Y; Inoue S
Horm Cancer; 2013 Aug; 4(4):222-32. PubMed ID: 23526455
[TBL] [Abstract][Full Text] [Related]
38. Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth.
Izzo F; Mercogliano F; Venturutti L; Tkach M; Inurrigarro G; Schillaci R; Cerchietti L; Elizalde PV; Proietti CJ
Breast Cancer Res; 2014 Dec; 16(6):491. PubMed ID: 25479686
[TBL] [Abstract][Full Text] [Related]
39. Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism.
Goodman CR; Sato T; Peck AR; Girondo MA; Yang N; Liu C; Yanac AF; Kovatich AJ; Hooke JA; Shriver CD; Mitchell EP; Hyslop T; Rui H
Oncogene; 2016 Mar; 35(11):1373-85. PubMed ID: 26096934
[TBL] [Abstract][Full Text] [Related]
40. CCAAT/enhancer binding protein β negatively regulates progesterone receptor expression in human glioblastoma cells.
Hansberg-Pastor V; González-Arenas A; Camacho-Arroyo I
Mol Cell Endocrinol; 2017 Jan; 439():317-327. PubMed ID: 27663075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
